Management of Apixaban-Associated Intracranial Bleeding

First-Line Reversal Strategy: Andexanet Alfa

The American Heart Association and American Stroke Association recommend andexanet alfa as the first-line therapy for patients on factor Xa inhibitors presenting with major bleeding, particularly intracranial hemorrhage, with a strength of evidence rated as high 1, 2
Andexanet alfa reduces anti-factor Xa activity by 93-94% within 2-5 minutes of administration, according to the International Society on Thrombosis and Haemostasis guidelines 1
In the ANNEXA-I trial, 67% of patients receiving andexanet achieved excellent or good hemostatic efficacy at 12 hours compared to 53.1% with usual care, as reported by the Journal of Thrombosis and Haemostasis 1
The American College of Cardiology recommends not delaying andexanet administration for laboratory confirmation of apixaban levels in life-threatening bleeding situations like intracranial hemorrhage, with a level of evidence rated as strong 4

The European Society of Intensive Care Medicine recommends high-dose four-factor PCC (25-50 U/kg) immediately for apixaban-associated intracranial hemorrhage when andexanet alfa is not available, with a grade of recommendation rated as strong 6, 7
The American Heart Association and American Stroke Association support PCC use for DOAC-associated intracranial hemorrhage when specific reversal agents are unavailable, with a level of evidence rated as moderate 2
Clinical studies demonstrate 68-72% hemostatic efficacy rates with PCC for apixaban/rivaroxaban-associated major bleeding, as reported by Critical Care 6, 7

The European Society of Cardiology notes that PCC carries increased risk of venous and arterial thrombosis (8.6-17% in studies), particularly with higher doses, with a level of evidence rated as high 6, 7
The American College of Cardiology recommends initiating thromboprophylaxis as early as possible after bleeding control is achieved, with a strength of evidence rated as strong 6, 7
The International Society on Thrombosis and Haemostasis guidelines state that the reversal effect of andexanet alfa is transient, with anti-factor Xa activity returning toward baseline approximately 2 hours after completing the infusion, with a level of evidence rated as high 3, 4